Literature DB >> 8355693

Control of BEK and K-SAM splice sites in alternative splicing of the fibroblast growth factor receptor 2 pre-mRNA.

E Gilbert1, F Del Gatto, P Champion-Arnaud, M C Gesnel, R Breathnach.   

Abstract

The fibroblast growth factor receptor 2 gene pre-mRNA can be spliced by using either the K-SAM exon or the BEK exon. The exon chosen has a profound influence on the ligand-binding specificity of the receptor obtained. Cells make a choice between the two alternative exons by controlling use of both exons. Using fibroblast growth factor receptor 2 minigenes, we have shown that in cells normally using the K-SAM exon, the BEK exon is not used efficiently even in the absence of the K-SAM exon. This is because these cells apparently express a titratable repressor of BEK exon use. In cells normally using the BEK exon, the K-SAM exon is not used efficiently even in the absence of a functional BEK exon. Three purines in the K-SAM polypyrimidine tract are at least in part responsible for this, as their mutation to pyrimidines leads to efficient use of the K-SAM exon, while mutating the BEK polypyrimidine tract to include these purines stops BEK exon use.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8355693      PMCID: PMC360257          DOI: 10.1128/mcb.13.9.5461-5468.1993

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  39 in total

1.  U1 snRNP targets an essential splicing factor, U2AF65, to the 3' splice site by a network of interactions spanning the exon.

Authors:  B E Hoffman; P J Grabowski
Journal:  Genes Dev       Date:  1992-12       Impact factor: 11.361

2.  Sex-specific alternative splicing of RNA from the transformer gene results from sequence-dependent splice site blockage.

Authors:  B A Sosnowski; J M Belote; M McKeown
Journal:  Cell       Date:  1989-08-11       Impact factor: 41.582

3.  Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer.

Authors:  M A Frohman; M K Dush; G R Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

4.  Rapid and quantitative preparation of cytoplasmic RNA from small numbers of cells.

Authors:  N M Gough
Journal:  Anal Biochem       Date:  1988-08-15       Impact factor: 3.365

Review 5.  Alternative splicing: a ubiquitous mechanism for the generation of multiple protein isoforms from single genes.

Authors:  R E Breitbart; A Andreadis; B Nadal-Ginard
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

6.  UACUAAC is the preferred branch site for mammalian mRNA splicing.

Authors:  Y A Zhuang; A M Goldstein; A M Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

7.  Nonsense mutations in the dihydrofolate reductase gene affect RNA processing.

Authors:  G Urlaub; P J Mitchell; C J Ciudad; L A Chasin
Journal:  Mol Cell Biol       Date:  1989-07       Impact factor: 4.272

8.  Effects of SV40 transformation on the cytoskeleton and behavioural properties of human keratinocytes.

Authors:  J Taylor-Papadimitriou; P Purkis; E B Lane; I A McKay; S E Chang
Journal:  Cell Differ       Date:  1982-05

9.  Statistical analysis of mammalian pre-mRNA splicing sites.

Authors:  M S Gelfand
Journal:  Nucleic Acids Res       Date:  1989-08-11       Impact factor: 16.971

10.  The role of the polypyrimidine stretch at the SV40 early pre-mRNA 3' splice site in alternative splicing.

Authors:  X Y Fu; H Ge; J L Manley
Journal:  EMBO J       Date:  1988-03       Impact factor: 11.598

View more
  31 in total

1.  Multiple splicing defects in an intronic false exon.

Authors:  H Sun; L A Chasin
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  The RNA-binding protein TIA-1 is a novel mammalian splicing regulator acting through intron sequences adjacent to a 5' splice site.

Authors:  F Del Gatto-Konczak; C F Bourgeois; C Le Guiner; L Kister; M C Gesnel; J Stévenin; R Breathnach
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

3.  Multiple interdependent sequence elements control splicing of a fibroblast growth factor receptor 2 alternative exon.

Authors:  F Del Gatto; A Plet; M C Gesnel; C Fort; R Breathnach
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

4.  Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family.

Authors:  Xiuqin Zhang; Omar A Ibrahimi; Shaun K Olsen; Hisashi Umemori; Moosa Mohammadi; David M Ornitz
Journal:  J Biol Chem       Date:  2006-04-04       Impact factor: 5.157

5.  hnRNP A1 recruited to an exon in vivo can function as an exon splicing silencer.

Authors:  F Del Gatto-Konczak; M Olive; M C Gesnel; R Breathnach
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

6.  The exon sequence TAGG can inhibit splicing.

Authors:  F Del Gatto; M C Gesnel; R Breathnach
Journal:  Nucleic Acids Res       Date:  1996-06-01       Impact factor: 16.971

7.  FGF2 posttranscriptionally down-regulates expression of SDF1 in bone marrow stromal cells through FGFR1 IIIc.

Authors:  Takayuki Nakayama; Noriko Mutsuga; Giovanna Tosato
Journal:  Blood       Date:  2006-10-31       Impact factor: 22.113

8.  Alternative splicing in fibroblast growth factor receptor 2 is associated with induced epithelial-mesenchymal transition in rat bladder carcinoma cells.

Authors:  P Savagner; A M Vallés; J Jouanneau; K M Yamada; J P Thiery
Journal:  Mol Biol Cell       Date:  1994-08       Impact factor: 4.138

9.  De novo alu-element insertions in FGFR2 identify a distinct pathological basis for Apert syndrome.

Authors:  M Oldridge; E H Zackai; D M McDonald-McGinn; S Iseki; G M Morriss-Kay; S R Twigg; D Johnson; S A Wall; W Jiang; C Theda; E W Jabs; A O Wilkie
Journal:  Am J Hum Genet       Date:  1999-02       Impact factor: 11.025

10.  Combined use of MS2 and PP7 coat fusions shows that TIA-1 dominates hnRNP A1 for K-SAM exon splicing control.

Authors:  Marie-Claude Gesnel; Fabienne Del Gatto-Konczak; Richard Breathnach
Journal:  J Biomed Biotechnol       Date:  2010-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.